Road Map for Business Continuity in Pharma

The Indian pharma sector is the third largest in the world. It manufactures almost 60 per cent of the vaccines used globally, including important ones, such as those against diphtheria, tetanus, and pertussis required by the World Health Organisation (WHO). Furthermore, the country meets 90 per cent of the global demand for the vaccine against measles.

Currently, generic drugs are playing a crucial role in the fight against COVID–19. India has been meeting more than 20 per cent of the world and almost 50 per cent of the US’s generic drug requirements. Unfortunately, Indian manufacturers rely heavily on China for key starting materials (KSMs), intermediate and APIs with China catering to nearly 70 per cent of Indian pharma companies’ requirements.

The Indian pharma sector is an important component of the global healthcare infrastructure and is instrumental in saving millions of lives every year. However, the lockdown triggered by coronavirus disease (Covid-19) has caused disruptions in all sectors. Pharma sector has been jolted too but there is hope that things will ease, and growth will resume.

The Economic Times Next Normal in Pharma themed on ‘’Road Map for Business Continuity in Pharma’’ is trying to gather the entire pharma industry value chain for indispensable discussion to connect and shape the future.

The programme will feature panels, one-to-one discussions, and keynotes, with disrupters, government, consultants and pharma professionals debating at the platform. The Economic Times Next Normal In Pharma will witness key stakeholder across organizations to reveal a holistic view of the challenges and enable cross-fertilization of knowledge.

This Webinar would highlight the core challenges and how the Indian healthcare system can overcome from the same by focusing on aspects below

• Initial Business Continuity Plans & how they have panned out
• Pharma experimenting and mastering alternative channels to doctors
• Managing Information: Ability to translate huge amount of digital information and decision making as a result
• Evolving into a Healthcare Digital Ecosystem from a traditional Pharma Company
• Challenges in digitalisation and solution
• Digital initiatives that are here to stay in pharma ecosystem – innovating for the new normal?
• Way Forward for India’s pharmaceutical Connect to External stakeholders

Speakers

Anandram Narasimhan
Managing Director
Merck (India Cluster)

Gagan Singh
MD
AstraZeneca Pharma India

Ganesh Ramachandran
Global CIO
Alkem Laboratories

Kiran Majumdar Shaw
Executive, Chairperson
Biocon

Manoj Kumar
Cluster Head, SVP
Intas Pharma

Manoj Saxena
Managing Director Bayer Zydus Pharma and Country Division Head
South Asia – Pharmaceuticals

Namita Thapar
Executive Director
Emcure Pharmaceuticals

Rajaram Narayanan
Managing Director
Sanofi India Limited

Rajiv Malik
President
Mylan

Sanjiv Navangul
MD & CEO
Bharat Serums and Vaccines

Sathya Prathipathi
Senior Partner
Mckinsey & Company

Saumil Mody
Country Head
India Oncology, Novartis

Sharad Tyagi
Managing Director
Boehringer Ingelheim India Pvt Ltd.

S. Sridhar
Managing Director
Pfizer Limited

Umang Vohra
Managing Director & Global Chief Executive Officer
Cipla Limited

Dr Vikas Gupta
Sr Vice President
Cipla

Vikrant Shrotriya
MD & CVP
Novo Nordisk

Vivek Khanvilkar
AVP
Sun Pharma

Agenda

15:45 – 16:00

Registration

16.00 – 16:05 

Opening Remarks by ET Edge

16:05 – 16.50

(PANEL 1)

Life Experiences & Guiding Light in COVID & Post COVID World

Umang Vohra, MD & Global CEO, CIPLA
Kiran Majumdar Shaw, Chairman, Biocon
Rajiv Malik, President, Mylan
Session Chair: Savitha Kuttan, CEO, Omnicuris

16:55 – 17:50

(PANEL 2)

Fireside Chat:  Lessons from COVID -19: Once in a lifetime event: Looking back
With marketing teams unable to visit and assess the market situation due to lockdown, companies are unable to take remedial measures to avoid short supply. Doctors are emotionally not ready to entertain MR and patients too. There are transport constraints as well, which does not make it easy for MRs to travel. Have there been innovative models of engagements that have come up now. How do we optimally engage HCPs in these settings? Given focus on productivity, efficiency and patient centricity.
Initial Business Continuity Plans & how they have panned out

  • Pharma experimenting and mastering alternative channels to doctors
  • Managing Information: Ability to translate large digital information and decision making as a result Evolving into a Healthcare Digital Ecosystem from a traditional Pharma Company

Sanjiv Navangul, MD, Bharat Serums
Vikrant Shrotiya, MD & CVP, Novo Nordisk
Manoj Saxena, MD, Bayer Zydus Pharma
Sharad Tyagi, MD, Boehringer Ingelheim
Session Chair: Savitha Kuttan, CEO, Omnicuris

17:50 – 17.55

Change over

17.55 – 18:35

(PANEL 3)

Panel Discussion: Digital initiatives are here to stay in pharma ecosystem – innovating for the new normal?
The COVID -19 has been an eye opener to us conveying how important its is to reboot our healthcare system. To adopt to the new normal innovation is a must. This discussion deep dives to detailed aspects of innovation which is highly vital to sustain and deliver.

  • Pharma Marketing Without Walls: Moving away from F2F Meetings
  •  Virtual capacity building of teams
  •  Steps to ensure business continuity
  •  Digital environments that are here to stay
  •  Balancing Between: Digital Tools| Consumer Engagement| Engaged Patients
  •  Sustainability of Digital Approach
  • What competencies have Pharma Sales Force developed in this transition

Ganesh Ramachandran, Global CIO, Alkem Laboratories
Dr Vikas Gupta, Sr Vice President, Cipla
Saumil Mody, Country Head & Oncology General Manager, Novartis 
Vivek Khanvilkar, AVP Sun Pharma
Manoj Kumar, Cluster Head, SVP, Intas Pharma
Session Chair: Savita Kuttan, CEO, Omnicuris

18:35 – 18:40

Change over
Anand has had an eventful career of around twenty years providing leadership in multi-national corporations across various functional domains. He brings a blend of managerial, technical, functional skills backed by a proven record in people management, developing strategy, business partnering and resource optimization.

He joined Merck as the as the regional controller in 2014 where he provided financial stewardship to the APAC business and guided the team to deliver aggressive growth and profitability expectations. His team set up robust systems & processes, analytical rigor, cross functional collaboration, strategic and functional thought leadership and has been instrumental in setting up processes to help monitor and drive the business. He has also worked on significant value creation and change management activities and on creating a diverse and strong finance community. At Merck he has been a key influencer for the adoption of the IBP processes, and also led the digital transformation agenda for the APAC commercial organization.

In his past mandate, he worked at Novartis as the Head of Business Planning for the International Region (Eastern Europe, Middle East, Africa, and Asia Pacific, 2011-14), and as the Head BPA India (2008-11) where he was instrumental in turning around the fledgling India OTC business. At Novartis he has rotated through roles in finance, strategy, and has also done a stint in sales. Prior to Novartis he worked in the advisory space with PwC and with Mahindra Satyam BPO where he headed finance and was a member of the management team that achieved a robust 90%+ year-on-year growth. He has also been an entrepreneur and headed his startup company.

Anand is an Associate Chartered Accountant from The Institute of Chartered Accountants of India. He holds an MBA in Analytical Finance, Strategy & Leadership from Indian School of Business and an Executive MBA in General Management from IMD School of Business. He is passionate about developing people and building winning teams.

Close
Ganesh is a digital transformation leader, who has helped set-up, grow and turn around businesses. He brings over 25 years of expertise across P & L management, management consulting and technology transformation.

With an in-depth exposure to best practices across all 3 levers that drive businesses – process, technology & people, he has helped clients evolve technology strategies to drive their business vision and transform their business, evaluate and extract business value from their technology investments. He has worked across the US, the Middle East, South East Asia and India.

In his current role as the Global CIO for Alkem Labs, Ganesh helps deploy digital technologies to drive sustainable profitable growth and capitalize on new opportunities and needs that have emerged with the changed market situation. Prior to Alkem Ganesh lead value advisory services for Consumer Products and Retail verticals for SAP India and was also the Managing Partner for Wipro Consulting services across India and the Middle East, wherein he doubled the business over a 5 year period. He has strong business development expertise both in India and the US. He lead Wipro’s Healthcare business development for the SouthWest of the US, was the managing consultant for Wipro’s consulting business in Western India, was the sales manager for Bangalore city for Pepsi and the Marketing lead for direct marketing of credit cards for Standard Chartered Bank for India.

He brings exposure across diverse industries including FMCG, Financial Services, Healthcare, IT Services and Government, and has assisted clients across process, technology, culture and change management, key facets of large transformative programs that he has worked on.

An analytical and strategic thinker, Ganesh is a Six sigma black belt, a Strengths certified coach and a Lead Auditor for Information Security. By qualification he is an engineer and an MBA.

You can connect with Ganesh on LinkedIn @ www.linkedin.com/in/rganeshdigitalead

Close
Ms Kiran Mazumdar-Shaw is a pioneering biotech entrepreneur, a healthcare visionary, a global influencer and a passionate philanthropist. She is a pioneer of India’s biotech industry and founder of Biocon.

Ms. Mazumdar-Shaw is the proud recipient of two of India’s highest civilian honours, the Padma Shri (1989) and the Padma Bhushan (2005). She was also honoured with the Order of Australia, Australia’s Highest Civilian Honour in January 2020. In 2016, she was conferred with the highest French distinction – Knight of the Legion of Honour.

She has recently been named as the winner of EY World Entrepreneur of the Year™ 2020 Award, which is a testimony to her entrepreneurial journey of over four decades. She has been ranked as one of the world’s top 20 inspirational leaders in the field of biopharmaceuticals by The Medicine Maker Power List 2020.

She holds key positions in various industry, educational, government and professional bodies globally. She has been elected as a full-term member of the Board of Trustees of The Massachusetts Institute of Technology (MIT), USA. She has been elected as a member of the prestigious USA based National Academy of Engineering (NAE).

She also serves on the Board of Infosys Ltd, Narayana Hrudayalaya Ltd and PureTech Health PLC.
Ms Mazumdar-Shaw holds a bachelor’s degree in science (Zoology Hons.) from Bangalore University and has earned a master’s degree in malting and brewing from Ballarat College, Melbourne University. She has been awarded with several honorary degrees from the Universities of repute globally.

Ms Mazumdar-Shaw believes in compassionate capitalism and is the first woman business leader from India to sign the Giving Pledge, an initiative of the Gates Foundation, committing to give the majority of her wealth to philanthropic causes.
She is very passionate about innovation and mentors many science-based start-ups.

Close
In April 2017, Manoj Saxena took over as Managing Director – Bayer Zydus Pharma and Country Division Head, South Asia – Pharmaceuticals.
As part of Bayer’s Asia Pacific Leadership Team, he is known for his contribution in driving key growth strategies within the region. With a deep understanding of the healthcare industry, he has wide experience across functions and has taken on senior roles in sales and marketing, business analysis and general management.

In his previous role, since July 2015 Manoj was the Managing Director of Bayer Co. (Malaysia) Sdn. Bhd. and Country Division Head of Pharmaceuticals for the diverse cluster of Singapore & Malaysia. He was also a Board Member of Singapore Association of Pharmaceutical Industries (SAPI).
Prior to that, in August 2012, he was the Country Head for Pharmaceuticals Division and the Country Representative for Consumer Health and Animal Health divisions in Bayer Vietnam. Here, he was the Board Member (Vice Chair) at Pharma Group Vietnam – a key industry association for the pharmaceutical industry.

Starting his career in the pharmaceutical industry with Cipla Ltd. in 1997 as a Management Trainee in Varanasi, he has held various positions of increasing responsibilities in commercial functions before moving to Cipla’s headquarters in April 2001. In his various roles, Manoj has had opportunities to work closely on Indian domestic strategy, new launches, new SBE’s and various other organizational projects from time to time. By the end of his tenure at Cipla, he was successfully managing 6 SBE’s with a business of over 150 m UD.

Manoj joined Bayer India in 2009 as the Business Unit Head for General Medicine and Women’s Health with a vision to expand and increase the footprint of Bayer in the emerging market. He strongly supported Bayer’s joint venture with Zydus Cadila in 2011 to form Bayer Zydus Pharma. He was then part of the Bayer Leadership Team in India and an active member of Organization of Pharmaceutical Producers of India (OPPI).

Manoj is a graduate with a Bachelor Degree in Mathematics (Hons) from the Banaras Hindu University, India. He has also completed his Masters in Business Administration (MBA) in Marketing. He currently resides in Mumbai along with his wife and daughter.

Close
Mrs. Namita Thapar is the Executive Director of Emcure Pharmaceuticals. Post her 6 year stint at Guidant Corporation, USA, Namita joined Emcure as CFO and subsequently her responsibilities grew to include Emcure’s India Business as well. Emcure Pharmaceuticals is a global pharmaceutical company headquartered in Pune with a turnover of 6000 crores ($750 million). It has presence in 70 countries and an employee strength of over 10,000.

Namita is a recipient of various prestigious corporate awards such as The Economic Times ‘40 under Forty’ award, Barclays Hurun Next Gen Leader recognition, Economic Times 2017 Women Ahead List, World Women Leadership Congress Super Achiever award.
She leads an active and busy life beyond her corporate role. She is a part of various government initiatives such as ‘Women Entrepreneurship Platform’ and ‘Digital Health Task Force’ by NITI Aayog and ‘Champions of Change’ program initiated by PM Narendra Modi for G2B partnership in policymaking.

Namita has been a speaker at various prestigious forums such as Harvard Business School, Indian Institute of Management (IIM- A), ET women’s conference, FICCI etc. She is also on the board of the Fuqua School of Business (Duke University). She is a member of Young Presidents Organization.

She is passionate about youth entrepreneurship and founded Incredible Ventures Ltd, an education company that teaches entrepreneurship to 11 -18 year olds in Mumbai, Delhi, Bangalore, Pune, Chennai and Ahmedabad.

Namita is an MBA graduate from the Fuqua School of Business and a Chartered Accountant from ICAI.

Close
Sanofi is one of the world’s leading healthcare companies with a global turnover of over 35 billion euros annually. The Company has been in India for over 60 years (established in 1956 as Hoechst Pharmaceuticals). The portfolio covers a wide range of medicines, including vaccines, medicines for chronic diseases such as diabetes, hypertension, as well as life saving treatment for rare diseases. In India, Sanofi employs over 5000 people across the field, 3 factories and management offices. In the last 10 years, Sanofi group has invested over Rs.5000 crores in India behind setting up new facilities, upgrading existing ones and in acquisitions.

Rajaram joined Sanofi in 2014. Over the last 6 years, he has led the strategic agenda for Sanofi in India leading to accelerated growth in key therapies, setting up of new business models and significant transformation of its market operations. He is also an Executive Committee member of the OPPI (Organisation of Pharmaceutical Producers of India).

Close
Rajiv Malik is president of Mylan and also serves on the company’s board of directors. Malik has more than 35 years of experience in the global pharmaceutical industry. He leads all global commercial and operational activities for the company, including sales and marketing in more than 165 countries and territories and operations that manage a portfolio of more than 7,500 marketed products, a pipeline of approximately 1,200 products and 47 manufacturing facilities around the world.

Malik is also responsible for the commercial and operational execution of Mylan’s growth areas, including the company’s antiretroviral (ARV)/infectious disease, biologics, dermatology, injectables, insulin analog, over-the-counter and respiratory platforms. Malik oversees business development, integration of acquired businesses and information technology with a focus on expanding and enhancing Mylan’s portfolio, product technologies and commercial capabilities.

Close
Managing Director and CEO
Sanjiv Navangul has led a host of global pharmaceutical companies to operational success. His mentorship and contribution towards a values-based culture is widely acknowledged by business leaders. Mr. Navangul has served on the board of Johnson & Johnson Pvt Ltd. India, and Fulford India. Mr. Navangul has held several leadership roles through his 30 year career such as Managing Director for Janssen (Pharmaceutical Division of Johnson & Johnson) in India and South Asia; Managing Director for MSD Pharmaceuticals, Philippines; Commercial Director for MSD India and South Asia.

A recipient of several industry awards on Public Health, Marketing and Diversity, Mr. Navangul has also served as the Vice President of OPPI (Organisation of Pharmaceutical Producers of India) from 2014 to 2019, Chairman of AMCHAM Pharma committee (American Chamber of Commerce) from 2016 to 2019 and Chairman, Medical and Regulatory Committee from 2016 to 2019. He has been on the Academic Board of NMMIS Pharma management, IES Management school and IIHMR, Jaipur.

Close
Sathya Prathipati is a Senior Partner at McKinsey & Company’s Mumbai office in India.

Sathya works with clients across industries, with a focus on pharmaceuticals and consumer goods.

Sathya leads McKinsey’s Pharmaceuticals Generics Practice globally and leads our Pharmaceutical and Healthcare Practice in India. He is the co-convener of the seminal Global Pharmaceuticals Generics industry CEO conference.

Sathya works with his clients on themes spanning performance improvement transformations, corporate strategy and technology enablement across China, India, Western Europe and the Americas.

Sathya has been a speaker at the Harvard Business School on Changing Landscape of Indian Healthcare, the International Generics CEO conference (Munich) on the future of the global Pharmaceutical Generics industry, as a key note at the Google-McKinsey digital health summit in India, the Asia Generics conference (Singapore) and a panelist on several conferences on topics spanning the global Generics industry, healthcare in India and the Indian consumer. He is the coauthor of the CII-McKinsey publication on ‘Healthcare 3.0’, the FICCI–McKinsey report on the Indian Lifesciences industry and several globally disseminated whitepapers on the pharmaceutical generics industry.

Examples of his recent client service include:

1. Developing the technology strategy roadmap for a top 3 consumer goods player in India
2. Developing the 5-year corporate strategy for an European generics company
3. Doubling margins of a business unit through a multi-faceted operations turnaround at a large Indian pharmaceutical company
4. Accelerating frontline sales growth for a leading Indian hospital chain and large Indian generic manufacturer
5. Leading the post-merger effort of two multi-billion dollar organizations to integrate their business functions and capture over $ 500 Mn of synergies
6. Leading the diligence of a US-based consumer asset as a strategic investment for an Indian conglomerate
7. Led the development and launch of a first of its kind technology platforms that achieved 80% adoption in the entire target population within the first week of launch

Prior to joining McKinsey, Sathya interned with the Technology, Media and Telecommunications desk of the Investment Banking Division (IBD) at Goldman Sachs & Co. in London.

Sathya received a Post Graduate Diploma in Management from the Indian Institute of Management-Bangalore (IIMB) and is a mechanical engineer by qualification

Close
Saumil is the Country Head and General Manager for Novartis Oncology and heads business operations for India, Srilanka, Nepal and Maldives. Along with this, he has additional responsibility as Head of Marketing and Commercial Excellence for Asia Cluster. He is a member of Country Leadership Team of Novartis in India.

Saumil has 25 years of experience in pharma industry, spearheading businesses growth for leading organizations in the industry. He has been a part of leadership teams for almost a decade. With his rich experience, Saumil specializes in navigating growth strategies in complex healthcare markets through commercial effectiveness and effective stakeholder management.

Before joining Novartis, Saumil worked with Esai Pharmaceuticals, one of the leading Japanese pharmaceutical companies, as the Senior Vice President for Commercial Operations. He was associated with Roche for more than 11 years and was responsible for strategising and developing the Oncology business of Roche India; Frost & Sullivan awarded Roche India, the Best Oncology Company for three consecutive years, under his leadership. Prior to this, Saumil was associated with Johnson & Johnson and Eli Lilly and company, in managerial roles.

Saumil holds a Master’s degree in Business Administration and Marketing Management from Symbiosis Institute of Management Studies. He has completed his Bachelor’s degree in Pharmaceutical Sciences from K.M. Kundnani college of Pharmacy

Close
Sharad Tyagi has over thirty five years of experience that spans across pharmaceuticals, personal care, automotive, environmental technologies & chemical industries. He has expertise in creating organizations and businesses from start-up and has extensive global business experience including Middle East, Asia, Europe and U.S.

After an engineering degree from Delhi University, Sharad completed his PGDM from the Indian Institute of Management (IIM), Ahmedabad in 1985 and began his career with ICI. After successfully setting up the Personal Care business in the Specialty Chemicals division of ICI, he joined Engelhard Corporation in 1996 as the Country Manager for India and Head of Strategy for Asia, positions he held for over ten years. During this period, he was instrumental in setting up one of the earliest catalytic converters operations and businesses in India and China. He then went on to head Marketing and Sales for the global API business of Dr. Reddy’s Labs Ltd.

For the past 10+ years, Sharad has been executing Boehringer Ingelheim‘s high-growth strategy for India, which involved launch of new innovation brands in Human Pharmaceuticals, synergising the Boehringer Ingelheim – Lupin alliance for diabetes and launch of the Animal Health Business.

Sharad is also the President of Organisation of Pharmaceutical Producers of India (OPPI) since April 2020

Close
Mr. S. Sridhar, Managing Director of Pfizer Limited, is leading Pfizer Inc’s commercial business in India having market capitalisation of US $ 2.7 billion. He is a member of the Pfizer Inc. Global Blueprint Leaders Forum and the Pfizer Asia Emerging Market Leadership Team.

Sridhar’s current responsibility pans across Pfizer’s off patent and innovative portfolio. He has in his career successfully steered many strategic projects, global brand launches, business restructuring actions, Mergers & Acquisitions, Joint Ventures, Pricing & Access initiatives. Sridhar is a strong people’s man and leads the Colleague engagement/ Culture work stream for Pfizer India.

Sridhar is a Chartered Accountant with 27 years of experience. He has successfully donned multiple hats in his career as Chief Financial Officer, Business Unit and Supply Chain Head and now the Managing Director of Pfizer India business since March 2016.

Sridhar is an Executive Member of Organisation of Pharmaceutical Producers of India (an association of Research Based Organisations) and is also the Chair of its Finance and Taxation Work Group. He is also the Chair of The Federation of Indian Chambers of Commerce and Industry (FICCI) Pharma Committee.

Prior to joining Pfizer, Sridhar spent 13 years with Diageo, the world’s largest alcoholic beverages company. He was the Finance Director when he left Diageo India.

Outside of office, Sridhar loves to cook and spend time in his second home in a tribal belt in the outskirts of Mumbai.

Close
Umang Vohra has been Managing Director and Global Chief Executive Officer (MD & GCEO) of Cipla since September 2016. Umang joined Cipla in October 2015 as its Global Chief Financial Officer, and from January 2016 to August 2016 was Cipla’s Global Chief Operating Officer.
After gaining degrees in engineering, marketing and finance, Umang was associated with companies such as Eicher Motors and PepsiCo. Prior to joining Cipla, Umang was Head of the North America business for Dr. Reddy’s Laboratories. Through his previous roles in India and the USA, he has built a distinguished career spanning almost two decades with deep understanding and experience in various aspects of the global pharmaceutical business.

Under Umang’s leadership, Cipla has built strong momentum in its home markets, augmented its capability, strengthened its core, and shown significant improvement in its operating margin and profitability. At the helm of the Management Council of Cipla, Umang’s big-picture agenda is to define and execute Cipla’s strategic growth roadmap and geographical footprint, identify the next levers of growth, invest in innovation for the future, and build the right organisation. Recognised as an action-oriented industry leader, Umang is a firm believer in the power of agile business models, disruptive technologies, data-driven analytics and a future-ready workforce with a view to shaping the healthcare ecosystem and making a difference to the lives of patients.

Close
Dr Vikas Gupta as head of Cipla India prescription business which makes up the biggest chunk of domestic sales. Vikas has over 20 years of experience in different therapies and business transformation interventions across various geographies
Vikas’ expertise includes delivery of profitable and sustainable top line by driving teams, innovative sales & marketing plans and creating mega brands.

In his earlier stint he used to lead the Acute Therapy business for Cipla and has led business roles across therapy areas including chronic, metabolic disorders and respiratory portfolio at Glenmark and Ranbaxy for India and international markets.

Close
Vikrant Shrotriya is the Managing Director & Corporate Vice President for Novo Nordisk’s India business. He is based in Bengaluru.

Vikrant has a distinguished career spanning over 20 years in the healthcare industry, in India and internationally. He has studied at Delhi University and Symbiosis Institute of International Business (SIIB), Pune and has worked in many national and international organisations in India, South East Asia and more recently in the GCC (Gulf Cooperation Council) countries where he was VicePresident for Novo Nordisk’s GCC business and Corporate Vice President for Saudi Arabia.

Vikrant has been honoured with several accolades throughout his career. Most recently, he received one of the highest awards from the Danish Government – “His Royal Highness Prince Henrik’s Medal of Excellence” – in recognition for his outstanding contribution to business and trade.

Close